Re: Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer

Journal of Urology

Volumn 185, Issue 6, 2011, Pages 2430-2432

  Langley, Ruth E ^a   Cafferty, Fay H ^a   Pollock, Philip A ^a   Price, Patricia ^a   Abel, Paul D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN; GONADORELIN AGONIST; POLYESTRADIOL PHOSPHATE; TESTOSTERONE; TOREMIFENE;

ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG FATALITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; FRAIL ELDERLY; HEALTH CARE COST; HUMAN; LETTER; OSTEOPOROSIS; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RISK REDUCTION; THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 79955817943     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2011.02.036     Document Type: Letter

References (8)

1. M.R. Smith Androgen deprivation therapy for prostate cancer: new concepts and concerns Curr Opin Endocrinol Diabetes Obes 14 2007 247
2. J.L. Ockrim, and P.D. Abel Long term androgen deprivation therapy in prostate cancer BMJ 337 2008 a1361
3. A.M. Bayoumi, A.D. Brown, and A.M. Garber Cost-effectiveness of androgen suppression therapies in advanced prostate cancer J Natl Cancer Inst 92 2000 1731
4. P.O. Hedlund, J.E. Damber, and I. Hagerman Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer; part 2 Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 42 2008 220
5. J.L. Ockrim, E.N. Lalani, and M.E. Laniado Transdermal estradiol therapy for advanced prostate cancerforward to the past? J Urol 169 2003 1735
6. J.L. Ockrim, E.N. Lalani, and L.M. Banks Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer J Urol 172 2004 2203
7. PATCH (MRC PRO9) A randomised controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancer http://www.ctu.mrc. ac.uk/research-areas/study-details.aspx?s=23
8. Langley RE, Kynaston H, Clarke N, et al. PATCH, a randomised phase II trial of oestrogen patches versus LHRH as first-line hormonal therapy for prostate cancer: planned interim analysis results. Presented at annual American Society of Clinical Oncology Genitourinary Cancers Symposium, Orlando, Florida, February 2628, 2009.